Filing Flows › Embecta (EMBC) › Q3 FY26 › vs Q2 FY26
Embecta (EMBC) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Embecta's revenue rose $49.9M (+22%) from $222M in Q2 FY26 to $272M in Q3 FY26. The biggest changes: Pen Needles +$22.8M (+15%); Other +$11.6M (+290%); Syringes +$10.3M (+39%). Gross margin 56.4% against 57.6% (-1.2 pts).
Embecta, Q3 FY26: revenue $272M (-8% year over year), operating margin 17.9%, net earnings $21.1M, operating cash flow $41.8M. The chart draws each line against Q2 FY26, the increases inside each band.
Margins
| Q3 FY26 | Q2 FY26 | Change | |
|---|---|---|---|
| Gross margin | 56.4% | 57.6% | -1.2 pts |
| Operating margin | 17.9% | 15.8% | +2.1 pts |
| Net margin | 7.8% | -1.8% | +9.6 pts |
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Pen Needles | $178M | $155M | $22.8M | +15% |
| Safety | $36.7M | $34.3M | $2.4M | +7% |
| Syringes | $36.6M | $26.3M | $10.3M | +39% |
| Other | $15.6M | $4.0M | $11.6M | +290% |
| Contract Manufacturing | $5.3M | $2.5M | $2.8M | +112% |
| Revenue | $272M | $222M | $49.9M | +22% |
| Gross profit | $153M | $128M | $25.5M | +20% |
| Cost of revenue | $118M | $94.0M | $24.4M | +26% |
| Operating profit | $48.7M | $35.0M | $13.7M | +39% |
| Operating expenses | $105M | $92.8M | $11.8M | +13% |
| Pre-tax earnings | $27.6M | $9.5M | $18.1M | +191% |
| Other expense, net | $21.1M | $25.5M | −$4.4M | -17% |
| Research & development | $5.6M | $5.4M | $200K | +4% |
| SG&A | $78.6M | $76.2M | $2.4M | +3% |
| Other operating costs | $20.4M | $11.2M | $9.2M | +82% |
| Net earnings | $21.1M | −$4.1M | $25.2M | — |
| Income tax | $6.5M | $13.6M | −$7.1M | -52% |
| Depreciation & amortization | $10.6M | $10.2M | $400K | +4% |
| Share-based compensation | $4.2M | $5.7M | −$1.5M | -26% |
| Working capital & other | $5.9M | $19.3M | −$13.4M | -69% |
| Operating cash flow | $41.8M | $31.1M | $10.7M | +34% |
Questions
How much did Embecta's revenue grow quarter over quarter in Q3 FY26?
Embecta's revenue rose $49.9M (+22%) from $222M in Q2 FY26 to $272M in Q3 FY26.
What drove Embecta's revenue change in Q3 FY26?
Pen Needles +$22.8M (+15%); Other +$11.6M (+290%); Syringes +$10.3M (+39%).